s-adenosylhomocysteine and Hypertension

s-adenosylhomocysteine has been researched along with Hypertension* in 3 studies

Reviews

1 review(s) available for s-adenosylhomocysteine and Hypertension

ArticleYear
The Adenosinergic System as a Therapeutic Target in the Vasculature: New Ligands and Challenges.
    Molecules (Basel, Switzerland), 2017, May-06, Volume: 22, Issue:5

    Topics: Adenosine; Cardiovascular System; Humans; Hypertension; Ligands; Molecular Targeted Therapy; Nucleoside Transport Proteins; Receptors, Purinergic P1; S-Adenosylhomocysteine; Vasoconstriction; Vasodilation

2017

Other Studies

2 other study(ies) available for s-adenosylhomocysteine and Hypertension

ArticleYear
Qian Yang Yu Yin Granule protects against hypertension-induced renal injury by epigenetic mechanism linked to Nicotinamide N-Methyltransferase (NNMT) expression.
    Journal of ethnopharmacology, 2020, Jun-12, Volume: 255

    Qian Yang Yu Yin Granule (QYYY) is a Chinese herbal formulation. It is used to treat hypertensive nephropathy for decades in China, but it is unknown that the exact mechanism of QYYY on hypertensive nephropathy.. The present study was to elucidate its epigenetic mechanism of QYYY on hypertensive nephropathy.. In the current study, HEK293T cells' proliferation induced by Ang II was chosen to observe epigenetic mechanisms of QYYY on renal damage. The cell proliferation was examined by MTT assays and ethynyldeoxyuridine analysis. Cell cycle analysis was performed. After treatment with QYYY, expression of Nicotinamide N-methyltransferase (NNMT), sirtuin1(SIRT1), S-adenosylhomocysteine(SAH), histone H3K4 methylation, and cortactin acetylation(acetyl-cortactin,ac-cortactin) were further investigated by western-blotting and real time PCR. DNA methylation was detected by ELISA. The study also observed the changes of SIRT1, SAH, H3K4 methylation, acetyl-cortactin when NNMT over-expressed by lentivirus transfection. Angiotensin II(Ang II) induced renal damage in spontaneously hypertensive rats(SHR). After eight weeks treatment of QYYY, blood pressure, serum and urine creatinine, and urinary microalbumin(mAlb) were assessed. The concentration of N1 -methylnicotinamide were detected by liquid chromatography with tandem mass spectrometry. The protein of NNMT, ac-cortactin, H3K3me3 were also assessed in vivo.. QYYY inhibited HEK293T cells' proliferation, down-regulated the expression of NNMT, SAH, acetyl-cortactin and DNA methylation, up-regulated the expression of SIRT1, histone H3K4 trimethylation(H3K4me3). Over-expression of NNMT increased the expression of SAH and acetyl-cortactin, and reduced the expression of SIRT1 and H3K4me3. The study also demonstrated that QYYY promoted urinary creatinine excretion and reduced serum creatinine and urinary mAlb in SHR. QYYY decreased the concentration of N1 -methylnicotinamide in Ang II group. QYYY decreased the protein of NNMT, ac-cortactin and increased H3K4me3 in vivo.. The results showed that QYYY alleviated renal impairment of SHR and inhibited HEK293T cells' proliferation induced by Ang II through the pathway of epigenetic mechanism linked to Nicotinamide N-Methyltransferase (NNMT) expression, including histone methylation, DNA methylation and acetyl-cortactin. This study unveiled a novel molecular mechanism by which QYYY controlled the progression of hypertensive nephropathy.

    Topics: Acetylation; Angiotensin II; Animals; Cell Proliferation; Cortactin; Disease Models, Animal; DNA Methylation; Drugs, Chinese Herbal; Epigenesis, Genetic; Epithelial Cells; HEK293 Cells; Histones; Humans; Hypertension; Kidney; Kidney Diseases; Male; Nicotinamide N-Methyltransferase; Rats, Inbred SHR; Rats, Inbred WKY; S-Adenosylhomocysteine; Sirtuin 1

2020
Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.
    American journal of physiology. Heart and circulatory physiology, 2006, Volume: 291, Issue:4

    The endogenous nitric oxide (NO) synthase (NOS) inhibitor asymmetrical dimethylarginine (ADMA) is elevated in many patients and may contribute to the initiation and progression of their disease. While some mechanistic pathways have been identified, tissue-specific contributions to ADMA control remain unclear. We sought to determine if whole blood (WB) could participate in ADMA control ex vivo. Anesthetized male Sprague-Dawley rats underwent exsanguinations, and WB preparations were incubated at 37 degrees C for 5 h. ADMA and symmetrical dimethylarginine were analyzed by high-pressure liquid chromatography. Incubation of lysed red blood cell (RBC) supernatant yielded a significant decrease in ADMA that was blocked by 4124W, a synthetic inhibitor of dimethylarginine dimethylaminohydrolase, the only reported enzyme to hydrolyze ADMA. Hydrolysis of ADMA was diminished by addition of physiologically relevant concentrations of zinc (i.e., 20 microM). Conversely, when rat WB or WB supernatant was incubated at 37 degrees C, it liberated quantities of free ADMA (1-2 microM) that in vivo would likely have pathological consequences. Addition of arginine methyltransferase inhibitors to these incubations did not reduce ADMA release, indicating no dominant role for active protein methylation during these incubations. This ADMA liberation was significantly reduced by addition of protease inhibitors, indicating a dependence on peptide bond hydrolysis. Total ADMA (protein incorporated plus free) was determined by acid hydrolysis and found to be 43.18 +/- 4.79 microM in WB with approximately 95% of this in RBCs. These ex vivo data demonstrate the potential of blood to control the NO-NOS system by modulating free ADMA.

    Topics: Aminobutyrates; Animals; Arginine; Blood; Endothelial Cells; Erythrocytes; Guanidines; Hypertension; Male; Nitric Oxide; Nitric Oxide Synthase; Rats; Rats, Sprague-Dawley; S-Adenosylhomocysteine; Zinc

2006